Skip to content

Effect of magnesium sulfate on anesthesia consumption and pain after spinal surgery

Comparison of different doses of Intravenous magnesium sulfate on intraoperative anesthetic drugs usage and post operative pain in Posterior Spinal Fusion surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230810059108N1
Enrollment
80
Registered
2023-08-21
Start date
2023-08-13
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnesium Sulfate. Other specified postsurgical states

Interventions

Intervention 1: First Intervention group (M1): At first, 50 mg/kg magnesium sulfate is given intravenous bolus for 15 minutes and then infusion of intravenous magnesium sulfate is 10 mg/kg/h. Interve

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years no history of drug sensitivity no history of thromboembolism no liver, heart or kidney failure, and coagulation disorders no anticoagulant drugs usage no severe obesity no neuromascular disease no calcium channel blockers usage physical class of American Society of Anesthesiology I,II (ASA) and patient satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Surgery time greater than 5 hours Changing the Surgical Procedure Bleeding more than 2 liters and requires massive transfusion Sustained blood pressure drop of more than 25% basal BP

Design outcomes

Primary

MeasureTime frame
Postoperative pain. Timepoint: 6.12.24 hours after surgery. Method of measurement: Numerical Rating Scale.

Secondary

MeasureTime frame
Dosage of Anesthetic Drugs. Timepoint: During surgery. Method of measurement: Bispectral Index.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeshat Abdi

Shahid Beheshti University of Medical Sciences

neshat.a15@gmail.com+98 912 078 6983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026